Clinical failure is an expected and understood fact in the quest to develop novel medicines, but recent stumbles by important candidates in late-stage trials at major firms are making the risk element of R&D more prominent than usual, with clinical disappointments threatening hopes for paradigm-changing treatment in Alzheimer’s disease, cardiovascular disease and hepatitis C.
Setbacks for pipeline centerpieces like Alzheimer’s candidates from Eli Lilly & Co. (solenezumab) and Johnson & Johnson/Pfizer...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?